Molecular therapy for Myocardial infarction: Nucleolin, a nucleolar phosphoprotein that plays a role in the maturation of ribosomes,  inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 20/August/2018, 7.21 pm

Combinatorial  therapy for human cancers: A pharmaceutical mixture encompassing Curcumin, Calcitriol, Amitriptyline, 17-DMAG, Temozolomide Berberine, Rosuvastatin, Salinomycin, (CCADTBRS) inhibits the expression of KAT6A and KAT6B, increases the expression of INK4a/ARF and other genes, promotes senescence, prevents cancer recurrence, and prolongs survival, via up-regulation of its target gene, 20/August/2018, 7.04  am
August 20, 2018
Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: PCGF2/Mel-18 increases the expression of tumor suppressors genes, such as  RECK, CADM1, p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 20/August/2018, 7.32 pm
August 20, 2018
Show all

What they say

A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of the journal Nature,  by Prof Dimmler, Boon, and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Myocardial infarction: Nucleolin, a nucleolar phosphoprotein that plays a role in the maturation of ribosomes,  inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS


price-300[easy_payment currency=”USD”]

From Significance of the study to Public Health Relevance:

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from  123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


From Research Findings to Therapeutic Opportunity

This study suggests, for the first time, that a nucleolar phosphoprotein Nucleolin may play a role in the delay of cardiac aging. A number of studies suggest Nucleolin may play a role in the control of cardiac diseases. However, the mechanism of action remains unclear.

Figure 1. Nucleolin functions as a Cardioprotective agent. Mechanistic insights into how Nucleolin induces the expression of PNUTS and Telomerase to prevent myocardial infarction and promote Cardiac regeneration/survival

Figure 2. Nucleolin functions as a myocardium-protecting agent through induction of cardio survival factor PNUTS

Nucleolin, by increasing the expression of its target genes, it may increase the expression of PNUTS (fig.1). Thereby, it may: (1) inhibit DNA damage responses, (2) increase telomerase expression, (3) inhibit telomere shortening; (4) promote cardiomyocyte survival/regeneration; (5) decelerate cardiac aging; and (6) extend lifespan (fig 1). 

 

 

 

 

 

 

Thus, by treating with compounds that induce the expression of  Nucleolin, one may prevent ageing-associated (or, stress-associated) decline in cardiac function. Together, this study suggests that (1) pharmacological formulations encompassing “Nucleolin inducers or their analogs, either alone or in combination with other drugs,”  may be used to improve cardiac function after myocardial infarction (fig. 2).


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Nucleolin increase the expression of PNUTS/Telomerase

Amount: $300#

# Research cooperation

For purchase and payment details, you may reach us at admin@genomediscovery.org


References

Web:http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L., Molecular therapy for Myocardial infarction: Nucleolin, a nucleolar phosphoprotein that plays a role in the maturation of ribosomes,  inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 20/August/2018, 7.21 pm,  Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.